Clinical Research Center, Department of Clinical Laboratory, Key Laboratory of Prevention and Management of Chronic Kidney Disease of Zhanjiang City, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Front Immunol. 2021 Dec 23;12:792884. doi: 10.3389/fimmu.2021.792884. eCollection 2021.
Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are two common multisystem autoimmune diseases that share, among others, many clinical manifestations and serological features. The role of long non-coding RNAs (lncRNAs) has been of particular interest in the pathogenesis of autoimmune diseases. Here, we aimed to summarize the roles of lncRNAs as emerging novel biomarkers and therapeutic targets in SLE and RA. We conducted a narrative review summarizing original articles on lncRNAs associated with SLE and RA, published until November 1, 2021. Based on the studies on lncRNA expression profiles in samples (including PBMCs, serum, and exosomes), it was noted that most of the current research is focused on investigating the regulatory mechanisms of these lncRNAs in SLE and/or RA. Several lncRNAs have been hypothesized to play key roles in these diseases. In SLE, lncRNAs such as GAS5, NEAT1, TUG1, linc0949, and linc0597 are dysregulated and may serve as emerging novel biomarkers and therapeutic targets. In RA, many validated lncRNAs, such as HOTAIR, GAS5, and HIX003209, have been identified as promising novel biomarkers for both diagnosis and treatment. The shared lncRNAs, for example, GAS5, may participate in SLE pathogenesis through the mitogen-activated protein kinase pathway and trigger the AMP-activated protein kinase pathway in RA. Here, we summarize the data on key lncRNAs that may drive the pathogenesis of SLE and RA and could potentially serve as emerging novel biomarkers and therapeutic targets in the coming future.
系统性红斑狼疮 (SLE) 和类风湿关节炎 (RA) 是两种常见的多系统自身免疫性疾病，除其他外，它们具有许多临床表现和血清学特征。长链非编码 RNA (lncRNA) 的作用在自身免疫性疾病的发病机制中尤为引人注目。在这里，我们旨在总结 lncRNA 作为新兴的新型生物标志物和治疗靶点在 SLE 和 RA 中的作用。我们对截至 2021 年 11 月 1 日与 SLE 和 RA 相关的 lncRNA 的原始文章进行了叙述性综述。基于对样本（包括 PBMCs、血清和外泌体）中 lncRNA 表达谱的研究，目前的大多数研究都集中在研究这些 lncRNA 在 SLE 和/或 RA 中的调节机制上。有几个 lncRNA 被假设在这些疾病中发挥关键作用。在 SLE 中，GAS5、NEAT1、TUG1、linc0949 和 linc0597 等 lncRNA 失调，可能作为新兴的新型生物标志物和治疗靶点。在 RA 中，许多经过验证的 lncRNA，如 HOTAIR、GAS5 和 HIX003209，已被确定为具有诊断和治疗潜力的新型生物标志物。例如，GAS5 等共享的 lncRNA 可能通过丝裂原活化蛋白激酶途径参与 SLE 的发病机制，并在 RA 中触发 AMP 激活蛋白激酶途径。在这里，我们总结了可能驱动 SLE 和 RA 发病机制的关键 lncRNA 的数据，它们可能在未来成为新兴的新型生物标志物和治疗靶点。
